Kestra Private Wealth Services LLC Purchases 8,069 Shares of Pfizer Inc. (NYSE:PFE)

Kestra Private Wealth Services LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.8% during the 4th quarter, HoldingsChannel reports. The firm owned 296,263 shares of the biopharmaceutical company’s stock after purchasing an additional 8,069 shares during the period. Kestra Private Wealth Services LLC’s holdings in Pfizer were worth $7,860,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PFE. Ritholtz Wealth Management lifted its position in shares of Pfizer by 26.3% in the third quarter. Ritholtz Wealth Management now owns 55,267 shares of the biopharmaceutical company’s stock worth $1,599,000 after purchasing an additional 11,519 shares in the last quarter. Retirement Planning Group LLC acquired a new stake in shares of Pfizer during the 3rd quarter worth about $354,000. Exchange Traded Concepts LLC lifted its holdings in Pfizer by 117.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 69,178 shares of the biopharmaceutical company’s stock worth $2,002,000 after purchasing an additional 37,293 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in shares of Pfizer in the third quarter valued at about $4,370,000. Finally, McGlone Suttner Wealth Management Inc. boosted its holdings in Pfizer by 17.7% in the 3rd quarter. McGlone Suttner Wealth Management Inc. now owns 15,378 shares of the biopharmaceutical company’s stock valued at $445,000 after purchasing an additional 2,311 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $25.76 on Monday. The stock has a 50-day moving average price of $26.28 and a two-hundred day moving average price of $27.73. The company has a market capitalization of $145.96 billion, a PE ratio of 18.27, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the company earned $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.68%. Pfizer’s payout ratio is presently 121.99%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PFE. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.